About Flavin-containing monooxygenase 5
Flavin-containing monooxygenase 5 (FMO5) is a protein
from Homo sapiens identified by UniProt accession
P49326, 533 residues long.
MolForge cross-references it against 0 known binders and
690 disease associations.
Target properties
| Protein name | Flavin-containing monooxygenase 5 |
| UniProt accession | P49326 |
| Gene | FMO5 |
| Organism | Homo sapiens |
| Length | 533 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (690)
Diseases linked to this target (Open Targets).
- body height · score 0.33
- appendicular lean mass · score 0.20
- type 2 diabetes mellitus · score 0.18
- diabetes mellitus · score 0.14
- infection · score 0.09
- infect · score 0.09
- granulocyte count · score 0.08
- adolescent idiopathic scoliosis · score 0.07
- neoplasm · score 0.07
- body weight · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49326-F1 | alphafold | PREDICTED | 94.96 | — |
Amino-acid sequence (533 residues)
MTKKRIAVIG GGVSGLSSIK CCVEEGLEPV CFERTDDIGG LWRFQENPEE GRASIYKSVI INTSKEMMCF SDYPIPDHYP NFMHNAQVLE YFRMYAKEFD LLKYIRFKTT VCSVKKQPDF ATSGQWEVVT ESEGKKEMNV FDGVMVCTGH HTNAHLPLES FPGIEKFKGQ YFHSRDYKNP EGFTGKRVII IGIGNSGGDL AVEISQTAKQ VFLSTRRGAW ILNRVGDYGY PADVLFSSRL THFIWKICGQ SLANKYLEKK INQRFDHEMF GLKPKHRALS QHPTLNDDLP NRIISGLVKV KGNVKEFTET AAIFEDGSRE DDIDAVIFAT GYSFDFPFLE DSVKVVKNKI SLYKKVFPPN LERPTLAIIG LIQPLGAIMP ISELQGRWAT QVFKGLKTLP SQSEMMAEIS KAQEEIDKRY VESQRHTIQG DYIDTMEELA DLVGVRPNLL SLAFTDPKLA LHLLLGPCTP IHYRVQGPGK WDGARKAILT TDDRIRKPLM TRVVERSSSM TSTMTIGKFM LALAFFAIII AYF
Explore Flavin-containing monooxygenase 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets